

# Marta Valle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4078630/publications.pdf>

Version: 2024-02-01

20  
papers

627  
citations

687363

13  
h-index

752698

20  
g-index

20  
all docs

20  
docs citations

20  
times ranked

923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. <i>Clinical Pharmacokinetics</i> , 2022, 61, 83-95.	3.5	2
2	Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 115-122.	1.2	1
3	Association of C677T and A1298C <i>MTHFR</i> Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 4263-4270.	1.1	9
4	Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. <i>Psychopharmacology</i> , 2019, 236, 573-580.	3.1	48
5	A systematic review of inpatient antimicrobial stewardship programmes involving clinical pharmacists in small-to-medium-sized hospitals. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, e69-e73.	1.1	24
6	Impact of clinical pharmacist intervention on antimicrobial use in a small 164-bed hospital. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, e46-e51.	1.1	11
7	Rupatadine oral solution for 2&ndash;5-year-old children with allergic rhinitis: a safety, open-label, prospective study. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 225-231.	3.4	14
8	Intrinsically regulated learning is modulated by synaptic dopamine signaling. <i>ELife</i> , 2018, 7, .	6.0	36
9	Assessing the Psychedelic ‘After-Glow’ in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 698-711.	2.1	111
10	Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children. <i>PLoS ONE</i> , 2017, 12, e0176091.	2.5	7
11	Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1528-1538.	2.4	5
12	Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 1161-1175.	0.7	123
13	Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw016.	2.1	25
14	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1139-1145.	3.0	21
15	Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv065.	2.1	46
16	Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 543-553.	3.5	32
17	Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2013-2019.	3.0	8
18	Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults. <i>Clinical Pharmacokinetics</i> , 2008, 47, 681-692.	3.5	42

#	ARTICLE	IF	CITATIONS
19	Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in HIV-Infected Patients in Routine Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 648-651.	2.0	36
20	Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naive, HIV-Infected Patients. <i>Antiviral Therapy</i> , 2006, 11, 47-51.	1.0	26